Cell Signaling Technology

Product Pathways - Wnt / Hedgehog / Notch

Dvl2 Antibody #3216

Applications Reactivity MW (kDa) Source
W IP H M R Mk Mi Hm 90 to 95 Rabbit

Applications Key:  W=Western Blotting  IP=Immunoprecipitation
Reactivity Key:  H=Human  M=Mouse  R=Rat  Mk=Monkey  Mi=Mink  Hm=Hamster
Species enclosed in parentheses are predicted to react based on 100% sequence homology. Species cross-reactivity is determined by Western blot.

Specificity / Sensitivity

Dvl2 Antibody detects endogenous levels of total Dvl2 protein. It does not cross-react with Dvl3.

Source / Purification

Polyclonal antibodies are produced by immunizing rabbits with a synthetic peptide (KLH-coupled) corresponding to residues surrounding Ser638 of human Dvl2. Antibodies are purified by protein A and peptide affinity chromatography.

Western Blotting

Western Blotting

Western blot analysis of total cell extracts from 293, COS, Mv 1 Lu, CHO and NICI-H1299 cells, using Dvl2 antibody.

Western Blotting

Western Blotting

Western blot analysis of total cell extracts from NIH/3T3 cells, untreated or treated with conditioned medium containing Wnt3a for 3 hours and also treated with or without lambda phosphatase, using Dvl2 Antibody.

Background

Dishevelled (Dsh) proteins are important intermediates of Wnt signaling pathways. Dsh inhibits glycogen synthase kinase-3β promoting β-catenin stabilization. Dsh proteins also participate in the planar cell polarity pathway by acting through JNK (1,2). There are three Dsh homologs, Dvl1, Dvl2 and Dvl3 in mammals. Upon treatment with Wnt proteins, Dvls become hyperphosphorylated (3) and accumulate in the nucleus (4). Dvl proteins also associate with actin fibers and cytoplasmic vesicular membranes (5) and mediate endocytosis of the Fzd receptor after Wnt protein stimulation (6). Overexpression of Dvl has been reported in certain cancers (7,8).

  1. Logan, C.Y. and Nusse, R. (2004) Annu. Rev. Cell Dev. Biol. 20, 781-810.
  2. Boutros, M. and Mlodzik, M. (1999) Mech. Dev. 83, 27-37.
  3. Lee, J.S. et al. (1999) J. Biol. Chem. 274, 21464-70.
  4. Itoh, K. et al. (2005) J. Biol. 4, 3.1-3.12.
  5. Capelluto, D.G. et al. (2002) Nature 419, 726-729.
  6. Chen, W. et al. (2003) Science 301, 1391-1394.
  7. Okino , K. et al. (2003) Oncol. Rep. 10, 1219-1223.
  8. Uematsu, K. et al. (2003) Oncogene 22, 7218-7221.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

Product Pathways

Drug Discovery Tools

Featured Technologies

Protein Classes